Romiplostim dose response in patients with immune thrombocytopenia

Journal of Clinical Pharmacology

Volumn 52, Issue 10, 2012, Pages 1540-1551

  Perez Ruixo, J J ^a   Green, B ^b   Doshi, S ^c   Wang, Y M ^c   Mould, D R ^b  

^a Amgen SA   (Spain)

^b Projections Research Inc   (United States)

^c AMGEN INC   (United States)

Author keywords

Immune thrombocytopenia; platelets; population pharmacodynamics; romiplostim

Indexed keywords

ROMIPLOSTIM;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REACTION TIME; SIMULATION; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; YOUNG ADULT;

EID: 84870424059     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011420843     Document Type: Article

References (37)

1. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood. 1993 ; 82: 1395-1401
2. Kaushansky K, Broudy VC, Lin N, et al. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A. 1995 ; 92: 3234-3238
3. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002 ; 100: 3457-3469
4. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994 ; 369: 568-571
5. Jin F, Krzyzanski W. Pharmacokinetic model of target-mediated disposition of thrombopoietin. AAPS PharmSci. 2004 ; 6: 1-8
6. Bunting S, Widmer R, Lipari T, et al. Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin. Blood. 1997 ; 90: 3423-3429
7. Hokom MM, Lacey D, Kinstler OB, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood. 1995 ; 86: 4486-4492
8. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001 ; 98: 3241-3248
9. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002 ; 99: 2599-2602
10. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996 ; 87: 4068-4071
11. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987 ; 80: 33-40
12. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol. 1996 ; 93: 704-706
13. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrompopoiesis- stimulating protein, for chronic ITP. N Engl J Med. 2006 ; 355: 1672-1681
14. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004 ; 76: 628-638
15. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999 ; 106: 345-356
16. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004 ; 25: 52-60
17. Nplate (Romiplostim) Investigator's Brochure. Thousand Oaks, CA: Amgen Inc ; 2009 :
18. Shirasugi Y, Ando K, Hashino S, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009 ; 90: 157-165
19. Samtani MN, Perez-Ruixo JJ, Brown K, Cerneus D, Molloy C. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose in healthy subjects. J Clin Pharmacol. 2009 ; 49: 336-350
20. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet. 2008 ; 371: 395-403
21. Beal SL, Sheiner LB NONMEM User's Guides. Hanover, MD: GloboMax LLC ; 1992 :
22. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002 ; 20: 4713-4721
23. van Kesteren C, Zandvliet AS, Karlsson MO, et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs. 2005 ; 23: 225-234
24. Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P, Steimer JL. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn. 2007 ; 34: 57-85
25. Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer RC, Steimer JL. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol. 2004 ; 58: 618-631
26. Ramon-Lopez A, Nalda-Molina R, Valenzuela B, Perez-Ruixo JJ. Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients. Pharm Res. 2009 ; 26: 1952-1962
27. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979 ; 25: 358-371
28. Glantz SA, Slinker BA Primer of Applied Regression and Analysis of Variance. New York, NY: McGraw Hill ; 1990 :
29. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007 ; 82: 17-20
30. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001 ; 28: 171-192
31. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006 ; 23: 2036-2049
32. Wang YM, Krzyzansky W, Doshi S, Xiao JJ, Pérez-Ruixo JJ, Chow AT. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 2010 ; 12: 729-740
33. Van Kesteren C, Zandvliet AS, Karlsson MO, et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs. 2005 ; 23: 225-234
34. Friberg LE, Freijs A, Sandström M, Karlsson MO. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther. 2000 ; 295: 734-740
35. Krzyzanski W. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J Pharmacokinet Pharmacodyn. 2011 ; 38: 179-204
36. Gabrielsson J, Jusko WJ, Alari L. Modelling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos. 2000 ; 2: 41-52
37. Jamali F, Lemery S, Ayalew K, et al. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology. 2009 ; 23: 704-709